Survivors of myocardial infarction are at risk of recurrent events and have an annual death rate of 5%. Advances in treatment and, in particular, the interventional management of myocardial infarction have seen important mortality gains over recent decades, yet cardiovascular diseases remain the biggest killer in many European countries. Change in lifestyle and adherence to medication to prevent further events are key to the recurrence of future events following myocardial infarction, but adherence to medication for the secondary prevention of cardiovascular disease is a profound problem. This article outlines a growing evidence base about the complex nature of adherence as a psychological phenomenon that is influenced by the nature of the event itself, illness perception and factors related to medication beliefs that cannot be addressed simply through a combination of educational approaches. A whole-systems approach is advocated, starting with the education of health professionals to understand the psychology of adherence, and to react comfortably to patients decisions about medication, with a pivotal role for follow-up in secondary care and cardiac rehabilitation.
Introduction
Each year in Europe alone, cardiovascular disease (CVD) causes over four million deaths, costing the economy a total of some 106 billion Euros; 29% of which is spent on medications. 1 Whilst advances in medication, changes in treatment and a decline in risk factors such as smoking have led to a large decline in mortality from coronary heart disease (CHD), CVDs remain the leading cause of death in many European countries. 2 Change in lifestyle and adherence to medication to prevent further events are key to the recurrence of future events following myocardial infarction (MI).
MI is one of the most dramatic presentations of CHD. 3 Each year more than seven million people worldwide experience MI; one-year mortality is around 10% and increases rapidly with age. 4 Survivors are at risk of recurrent events and have an annual death rate of 5% which is six times that in people of the same age who do not have CHD. 5 The efficacy of medication to reduce the risk of recurrent events is established through randomised controlled trials (RCTs); medications are the primary tools used to prevent and manage chronic illness, yet despite their importance and known benefit, appropriate medication use is a challenge for both recipients and providers of health care. There is evidence in most countries with available data that mortality and casefatality rates from CHD and stroke have decreased substantially over the last 5-10 years at differing rates. 2 It is likely that trends in longer-term survival are at least partially explained by the use and enforcement of European and national guidelines leading to increased medication prescribing in primary care. 6, 7 However, there is a need to consider that, having been prescribed appropriate medication for secondary prevention, in order to claim its potential benefit the medication regimen needs to be followed. Attention is turning to ways in which long-term adherence to medication to reduce the risk of recurrent events, can be supported.
Medication adherence
Medication adherence is defined as the extent to which people take medication as prescribed by health-care providers. 8 The terms 'compliance', 'concordance' and 'adherence' are all used to describe the extent to which patients take, or persist with, a medication regime; the term 'adherence' is used in consideration that people choose to take medication and have control over its use. Adherence refers to 'attachment' or 'commitment', sticking to a practice or tenet and suggests perseverance; it is a term that 'conjures up the tenacity that patients need to achieve in sticking to a therapeutic regimen' (p. 383). 9 Whilst prescribing rates have increased, patients frequently do not adhere to medications, resulting in poor clinical outcomes. 10 Adherence is a problem that exists across a spectrum of primary and secondary prevention of chronic diseases and presents a profound problem in people with CHD. Non-adherence is known to be associated with increased mortality with, for example, non-adherence to statins in the year after MI being associated with 12-25% increased hazard for mortality. 11 For patients discontinuing aspirin, statin and beta-blockers within the first year after MI, one-year survival reduces from 97.7% to 88.5%. 12 The scale of non-adherence to medication A meta-analysis of 376,162 patients prescribed medication for primary or secondary prevention of CHD across 20 studies demonstrates a summary estimate for adherence of 57% after a median 24 months after the initial prescription 13 irrespective of age, cost or class of drug. Data from the Global registry of Acute Coronary Events (GRACE) registry 14 identified across a sample of 13,830 acute coronary syndrome (ACS) patients that, after six months, 8% discontinue aspirin, 20% discontinue Angiotensin Converting Enzyme (ACE) inhibitors and 13% discontinue statins.
This article examines influences on adherence to secondary prevention medication after MI, and draws on the literature to propose the way forward to develop best practice in order to improve adherence to secondary preventive therapies. The article guides the reader through influences throughout the patient's journey during and following a heart attack, examining evidence that helps to explain and understand medication adherence. It offers consideration as to ways in which adherence can be actively addressed throughout the patient's presentation, recovery and longer-term care. The paper considers medication adherence from the perspective of patient characteristics, the nature of treatment, the patient's perception of the event, the role of follow-up care, and from a health system perspective.
Patient characteristics
Overall persistence is lower in older age than in other age groups. 15, 16 Jin et al. 16 evaluated age-related predictors in people less likely to adhere to medications, collecting data on sociodemographic characteristics, depressive symptoms and medication use by telephone by a telephone survey administered 18-24 months after an acute coronary event. Older patients (over 65 years) had a significantly increased under-use of medications compared with younger patients (under 65 years) including aspirin, ACE inhibitors/Angiotensin Receptor Blocker (ARB), beta blockers and statins. In older patients, factors associated with under use of medications included low educational level, a greater number of co-morbidities, and total number of discharge medications. In younger patients, low income and depression factored highly with high cost and fear of adverse effects cited as reasons for non-adherence. However, in other studies lower income was identified as being a predictor of improved adherence 17 reflecting that differing approaches to funding of long-term health costs may influence whether people continue to take medication. In an observational study by Kulkarni et al., 18 of 1326 patients with CHD undergoing angiography, for medications of all classes there was a significant decrease in use. More adherent patients in this study were more likely to be married, better educated, male, have higher mental test scores and fewer medications.
Other studies have highlighted the importance of complex medication regimes that are more likely in older patients and those with co-morbidities as well as a relationship between decline in medication adherence and depression 19, 20 and in patients with lower health literacy. 21 Social support has also been found to be an important predictor of medication adherence. 20 Follow-up with a cardiologist as the responsible physician and receipt of discharge medication counselling also appear to be important factors 17 in improving adherence.
Perception of the event and treatment
People adapt very differently to the experience of illness. Petrie and Weinman 22 state that 'patients with the same illness or injury can have widely different perceptions of their condition . . .' (p. 536). Understanding illness perception can lead some way to understanding an individual's cognitive adaptation to their illness, of which adherence to treatment is a key component. 22 A narrative review of studies evaluates the impact of illness perception across a range of conditions. 23 Higher scores in illness identity, meaning perception of more symptoms related to the condition, were associated with greater adherence. People who believed their condition to be cyclical were less adherent and those who had higher scores in both the timeline (believing the condition to be long lasting) and control (believing the condition to be influenced by both treatment and personal factors) domains were more adherent. Those who perceived their condition to have more serious consequences were more adherent to medication; this review whilst not focusing on MI patients identifies that it is likely that the individual's perception of their heart attack will have an important, but as yet not quantified, impact on medication adherence.
The current focus on immediate treatment of a sudden and acute MI with early percutaneous coronary intervention and, as a result, reduced length of hospital stay may have an impact on adherence, perhaps indirectly through impacting on illness perception. Astin et al. 24 evaluated illness perception of a group of patients who had undergone primary percutaneous coronary intervention (PPCI), with the results suggesting that they felt the event was an acute, 'one-off' event rather than a symptom of a chronic disease. Conversely, patients in a study by Yan et al. 25 had a longer hospital stay with low scores for illness coherence, meaning a poor understanding of the disease, and a belief that the illness had serious consequences, this time with a mean hospital length of stay of 11 days. These studies suggest that the nature of treatment and the length of hospital stay and perceived recovery will therefore impact on adherence.
Dullaghan et al. 26 added to this work; they established through interviews that the nature of the event itself and the approach to treatment will influence people's perception of the seriousness of the event. Those with ST-Elevation MI (STEMI) tended to see their illness as a serious life-threatening event, whereas those who had Non-STEMI experienced more uncertainty about symptoms and diagnosis; it is not yet clear how such differences in illness perception might impact on adherence to secondary preventive medication. Supporting the observation further is a meta-analysis 27 that detected a significant positive correlation between adherence and the perception of disease severity. A qualitative synthesis 28 noted that fatalistic beliefs about the illness tended to lead people to be nonadherent to medication, and the absence of symptoms in people who were recovered from MI tended to leave patients challenging the need for medication, implying a poor understanding of the need for long term secondary preventive therapies.
Factors related to medications
Negative beliefs about medication are significantly associated with medication adherence. 29, 30 Up to 20% of variance in adherence behaviour has been attributed to a patient's belief about medication, such as perception of medication necessity and concerns about the potential harmful effects of medications. 29, 31 For many this will resonate as an important feature of the hospital discharge or follow-up consultation. It is during hospitalisation that a patient will have medication initiated, often with minimal explanation but rarely with an opportunity for discussion, and during a short hospital stay and little late recall of conversations that may have taken place. It is implicit that the patient is expected to understand and continue medication after discharge.
After discharge a patient has the opportunity to reflect, to read and to discuss medication prescription with informed and less informed sources that might range from reinforcement to popular media influences on negative perception. It is known that social support can enforce the need for medication adherence, but also well observed that external influences can negatively impact on the individual's wish to persist with medication in the long term. Concerns about actual or potential medication side effects will compound negative rather than positive influences on adherence. This will inevitably lead to a greater likelihood that adherence will decline over time; it is a dislike of medication and wariness of long-term side effects that will influence the decision of some to adhere to medication. 28 This is likely compounded, particularly for people with multiple co-morbidities, in those for whom the complexity of the medication regimen and dose frequency additionally contribute to reduction in adherence. 32 
Relationships with prescribing clinicians
During the course of hospitalisation and follow-up, patients will encounter a variable number of cardiologists, physicians, general practitioners, cardiac rehabilitation practitioners, pharmacists and nurses among other health professionals and the provision of consistent and trusted information across health-care teams is invaluable in supporting a patient's recovery. It has been identified 14, 17 that patients who have a cardiologist as the responsible physician and who receive discharge counselling with respect to medication, are more likely to be adherent to medication. Further, there is evidence that early follow-up contact in secondary care can increase medication adherence. 28, 33, 34 Whilst it might be considered that medication adherence improves with early follow-up, it is not yet established how this creates so positive an impact.
There is a health system-wide policy drive away from the perceived costliness of follow-up in secondary care; coupled with early discharge and reduction in length of stay following MI, there is a limited amount of time for supporting patients with respect to recovery and medication during their hospital stay and therefore patients may receive less, rather than more, health professional support for longer-term medication adherence.
Given that patients do opt-out of follow-up with cardiac rehabilitation teams there will be a variation in the level of contact with health providers. It is nonetheless imperative that patients receive consistent and helpful support in achieving treatment targets for secondary prevention with medication, and that all providers are sufficiently versed in the need for, and the short and longer term effects of, medication offered for secondary prevention in order to support patients in their recovery. A growth in the number of professions able to prescribe may increase the number of health professionals better understanding the complexities of adherence and the skills to address adherence are welcome, although the impact on adherence of this expansion in allied health professional prescribing is yet to be studied. It is noted elsewhere 35 that the core European Society of Cardiology (ESC) curriculum for the cardiologist defines in detail the knowledge needed in regard to secondary prevention, but it is also noted that it is questionable whether such requirements are part of the curriculum of most cardiologists or specialist allied health professionals, including those who specifically can, or will be able to, prescribe for MI patients.
Interventions to support adherence
Nieuwlaat et al. 36 identified a total of 182 studies of interventions to improve medication adherence. They selected studies reporting a RCT comparing a group receiving an intervention to improve medicine adherence with a group not receiving the intervention, including trials that measured medicine adherence and a clinical outcome (e.g. blood pressure), with at least 80% of patients studied until the end. Reflecting the complexity of medication adherence, 17 studies of the highest quality were complex and included several different ways to try to improve adherence, including such strategies as enhanced support from family, peers or allied health professionals such as pharmacists, who often delivered education, counselling or daily treatment support. Only five of these studies reported improvements in both adherence and clinical outcomes, with no common characteristics among the studies; the authors conclude that even the most effective of the interventions did not lead to large improvements in adherence or outcome. Previous reviews have offered similar conclusions, that there are no studies that allow the identification of any simple or single approach to improving medication adherence that might be effective, and attempts to improve adherence using intervention by multiple approaches are potentially time intensive and therefore costly.
Qualitative reviews have also been offered. Kuntz et al. 37 included 60 qualitative studies that incorporated patient-centred approaches to medicines management, including shared decision-making, methods to enhance effective prescribing, systems for eliciting and acting on feedback about medicines use and treatment goals, and medication-taking behaviour; they concluded that the most effective interventions involved counselling, health coaching, motivational interviewing and self-monitoring through feedback on clinical values. Many of these interventions involved the delivery of education around the needs of the patient but, as with the review of RCTs, 36 did not identify important intervention beyond intensive support over time.
The role of technology
The role of technology in supporting medication adherence is starting to gather interest. The idea of using simple electronic reminders such as daily messaging or follow-up telephone calls is based on the premise that patients who do tend to forget medication will respond to prompting. However, the inherent problem with the efficacy of prompting in this way is that this suggests patients will forget to take, rather than choose not to take, medication. Technology-assisted interventions such as the use of smartphone or tablet applications ('apps') have shown some promise 38 and although potentially useful as patient aids, evidence of clinical benefit so far is largely anecdotal.
Conclusions: the way forward
Box 1 provides a summary of influences on adherence.
Medication adherence is incredibly complex. To describe the sociodemographic characteristics of patients might alert the clinician to the potential for poor adherence, but does not serve to help understand or address the phenomenon. Neither does a focus on research that addresses adherence specifically from an educational perspective; the simple provision of education in any form may seem a common-sense approach to adherence intervention, but belies its complexity. From the perspectives of the patient, the health professional and the health system, there are potentially many approaches that might help to improve adherence. Evidence supporting any great improvement in adherence as a result of any single intervention remains elusive and it is only a whole-system approach, with an understanding of what is a complex psychological phenomenon, to patient management and health-care thinking on a grander scale that will enable a difference.
The knowledge and understanding of the phenomenon that is medication adherence needs to be addressed for all health professionals that come into contact with people who have suffered MI. Only by acknowledging its complexity and making this understanding a mandatory and assessed part of all health professional curricula, will help to develop skills across professional groups to adopt a no-blame and patientfocused approach to supporting medication use.
Discussion about medication-taking, the aims of medication for secondary prevention including individualised treatment targets, establishing how people feel about medication, and addressing concerns should become an integral part of every consultation. The case study presented in Box 2 illustrates that patients may well be certain they are adherent to medication; indeed, this gentleman is within his own belief system although, whilst he protests that he is taking his medication, he is clearly not taking it in the way that it was intended.
Assessing peoples' understanding of the need for medication, their medication beliefs, illness perception and medication adherence along with adopting measurement tools such as the illness perception questionnaire 22 This patient is taking his tablets. His chest pain is exertional but also on questioning sometimes at rest; it is very atypical, varying in duration and severity and he has had successful intervention for stable symptoms. He is not taking his medication to the best effect but asserts he is taking medication. Advised: take omeprazole regularly. Stop ranolazine; stop diltiazem. Note interaction and poor adherence despite multiple contacts with health team. Early review arranged. The influence of the prescriber -profession, follow-up, rehabilitation, timing of follow-up, exposure to consistent advice.
The consultation -what is it about follow-up, the nature of the conversation, is adherence considered -does the patient feel the need to adhere because the doctor or nurse can tell -illness perception, health literacy. Informed choice -perceptions -media, family, dose and tailoring of medication -professional use of aggressive terms for secondary prevention. Multi-dosing, complex regimes, passage of timeimprove or decrease adherence. The role or potential impact of technology is yet to be evaluated. medication regimen into their life. Consideration could be given to those who might benefit from simple approaches to assessing adherence such as technological innovation, and for people with lower incomes financial support should be offered; health professionals should continue to lobby at a health policy level to provide parity of access to evidence-based treatments in the same way as in some countries, diabetes or asthma are considered to be supported long-term conditions with access to free medication.
Prescribers and all members of the health team need to understand the integral part in medication adherence that is played by the individual's beliefs about the necessity for, or potential harm that might be associated with, medication use, and be prepared to encounter and effectively deal with difficult challenges as to the need for, or perception of the potential harm coming from, medication.
Inconsistent information from health-care providers should be addressed in the provision of system-wide written and/or visual media supported by consistent verbal messages about medication. People learn to mistrust health professionals who offer differing information; the information made available should be based on evidencebased guidelines and reviewed as guidelines develop. Follow-up should be offered early and at a consistent level. The skills and confidence needed to evaluate medication adherence should be provided at every point of contact, which means that, where possible, the ability to prescribe, to adjust doses to suit individual patients and to de-prescribe, should be skills available to the patient at every point of contact, including follow-up in secondary and in primary care, and even more importantly, during cardiac rehabilitation, where the potential for ongoing active assessment and management of medication adherence is at its greatest in the early discharge period.
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